HEALTHY U CHIP

PRIOR AUTHORIZATION REQUEST FORM **LUNSUMIO™**

For authorization, please answer each question and fax this form PLUS chart notes back to the Healthy U CHIP Prior

Authorization Department at 801-213-1547. Failure to submit clinical documentation to support this request will result in a dismissal of the request. If you have medical pharmacy prior authorization questions, please call for assistance: 833-981-0212 Disclaimer: Prior authorization request forms are subject to change in accordance with Federal and State notice requirements. ID#: Date: Member Name: DOB: Gender: Physician: Office Phone: Office Fax: Office Contact: Height/Weight: Member must try formulary preferred drugs before a request for a non-preferred drug may be considered. If treatment with preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria. **Product being requested:** □ Lunsumio[™] (mosunetuzumab-axgb) Dosing/Frequency:__ If the request is for reauthorization, proceed to reauthorization section. Questions **Comments/Notes** Yes No 1. Does documentation show histologically confirmed diagnosis of Please provide documentation relapsing or refractory follicular lymphoma grade 1, 2, or 3A? 2. Does the member have an Eastern Cooperative Oncology Please provide documentation Group (ECOG) Performance status of 0 or 1? 3. Does documentation show no response or refractory to at least Please provide documentation 2 lines of systemic therapy, including both of the following: Anti-CD20 therapy • An alkylating containing regimen 4. Does the member have current or past central nervous system Please provide documentation (CNS) involvement? 5. For females with reproductive potential: Please provide documentation П • Is there documentation of a negative pregnancy test prior to the start of therapy? • Has the member been counseled on the use of effective contraception during treatment and advised of the pregnancy risks associated with treatment? **REAUTHORIZATION** 1. Is the request for reauthorization of therapy? П 2. Has the member had a complete response based on imaging Please provide documentation and bone marrow examination?

3. Does the member have a partial response on stable disease in			Please provide documentation
response to treatment with Lunsumio™ after 8 cycles?			
What medications and/or treatment modalities have been tried in the past for this condition? Please document			
name of treatment, reason for failure, treatment dates, etc.			
Additional information:			
Physician Signature:			

** Failure to submit clinical documentation to support this request will result in a dismissal of the request.**

Policy: PHARM-CHIP-M042 Origination Date: 07/01/2024 Reviewed/Revised Date: Next Review Date:

Current Effective Date: 07/01/2024

Confidentiality Notice

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.